94 related articles for article (PubMed ID: 16610938)
1. Genzyme launches diagnostic to monitor Gleevec resistance.
Pharmacogenomics; 2006 Apr; 7(3):267. PubMed ID: 16610938
[No Abstract] [Full Text] [Related]
2. Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia.
Pharmacogenomics; 2005 Jul; 6(5):458-9. PubMed ID: 16013994
[No Abstract] [Full Text] [Related]
3. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892
[No Abstract] [Full Text] [Related]
4. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C
Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211
[No Abstract] [Full Text] [Related]
5. Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Popovici C; Charbonnier A; Gisserot O; Aguilon P; Rémy V; Olschwang S; Mozziconacci MJ
Leuk Res; 2008 Feb; 32(2):361-2. PubMed ID: 17412419
[No Abstract] [Full Text] [Related]
6. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
7. Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
[No Abstract] [Full Text] [Related]
8. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
9. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
Tauchi T; Oyashiki K
Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
[No Abstract] [Full Text] [Related]
10. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
11. Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Travis J
Science; 2004 Jul; 305(5682):319-21. PubMed ID: 15256643
[No Abstract] [Full Text] [Related]
12. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
13. Exploiting oxidative damage to overcome resistance.
Karp JE; Smith BD
Leuk Res; 2006 Oct; 30(10):1213-4. PubMed ID: 16564572
[No Abstract] [Full Text] [Related]
14. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
Janssen JJ; Hochhaus A; van Oostveen JW; Waisfisz Q; Schuurhuis GJ; Ossenkoppele GJ
Leukemia; 2004 May; 18(5):1020-1. PubMed ID: 15014529
[No Abstract] [Full Text] [Related]
15. New-age drug meets resistance.
McCormick F
Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
[No Abstract] [Full Text] [Related]
16. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
17. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
18. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
[TBL] [Abstract][Full Text] [Related]
19. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
Sayed D; Badrawy H; Gaber N; Khalaf MR
Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
[TBL] [Abstract][Full Text] [Related]
20. Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.
Prebet T; Tigaud I; Hayette S; Clapisson G; Philip I; Michallet M; Nicolini FE
Haematologica; 2005 Nov; 90 Suppl():ECR36. PubMed ID: 16266927
[No Abstract] [Full Text] [Related]
[Next] [New Search]